Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$3.45 - $8.77 $284,625 - $723,525
-82,500 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$11.94 - $16.09 $11,940 - $16,090
-1,000 Reduced 1.2%
82,500 $1.04 Million
Q2 2020

Aug 13, 2020

BUY
$8.21 - $21.02 $67,322 - $172,364
8,200 Added 10.89%
83,500 $1.49 Million
Q1 2020

May 14, 2020

BUY
$7.81 - $18.82 $588,093 - $1.42 Million
75,300 New
75,300 $693,000
Q1 2019

May 15, 2019

SELL
$15.53 - $19.75 $726,027 - $923,312
-46,750 Closed
0 $0
Q4 2018

Feb 12, 2019

SELL
$15.58 - $28.41 $44,403 - $80,968
-2,850 Reduced 5.75%
46,750 $778,000
Q3 2018

Nov 13, 2018

SELL
$25.99 - $30.6 $25,990 - $30,600
-1,000 Reduced 1.98%
49,600 $1.4 Million
Q2 2018

Aug 07, 2018

SELL
$27.78 - $38.53 $41,670 - $57,795
-1,500 Reduced 2.88%
50,600 $1.43 Million
Q1 2018

May 09, 2018

BUY
$27.78 - $35.19 $770,895 - $976,522
27,750 Added 113.96%
52,100 $1.64 Million
Q4 2017

Feb 14, 2018

BUY
$23.33 - $35.01 $568,085 - $852,493
24,350
24,350 $710,000

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $71.5M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.